medmix intends to enter into a strategic investment in AARDEX Group

    October 17, 2023

    medmix (SIX: MEDX) today announced its intention to enter into a strategic investment, representing a 25% stake, in AARDEX to reinforce medmix' drug delivery business under the HaselmeierTM brand. AARDEX is a global Software as a Service (SaaS) provider of digital solutions for measuring and managing medication adherence in clinical trials.

    medmix Group AG (medmix), a world-leading manufacturer of high-precision delivery devices, announced it has signed an agreement for a 25% stake in AARDEX Group (AARDEX) through Series B investment. The transaction is expected to close by year end subject to customary process.

    AARDEX is the leading global player in digital medication adherence in clinical trials, having pioneered the development of the Medication Event Monitoring System (MEMS®). AARDEX offers its solutions with expertise and patents in the algorithms that analyze, visualize, and interpret patient’s adherence behaviors. AARDEX solutions have been used by over 1 million patients across more than 70 countries, in over 1,000 clinical research studies and 200+ drug trials, resulting in over 830 peer-reviewed publications. AARDEX customers are mainly in the US and Europe.

    “We are delighted to welcome medmix on board as a new shareholder in AARDEX. This collaboration marks a pivotal point in our pursuit of transforming digital medication adherence solutions” said David Dalla Vecchia, co-CEO and Financial Lead of AARDEX.

    Bernard Vrijens, co-CEO and Scientific Lead of AARDEX, added, “With the backing of medmix, our goal is to spearhead the sector by offering ground-breaking, data-centric solutions that enhance patient adherence and ensure data precision in drug studies. United, our vision is to reshape the landscape of drug trial processes, guaranteeing more dependable and precise outcomes for superior patient care.”

    Haselmeier and AARDEX together expanding market leadership
    Haselmeier and AARDEX, founding shareholders and management teams, will work closely together to provide an end-to-end service comprising digital adherence solutions jointly with delivery devices, for the benefit of their mutual and new customers. With the aim to grow the leading positions in the global drug delivery market.

    Dominik Vonier, Head of Drug Delivery at medmix, comments: “Medication adherence monitoring is fast becoming a priority for Pharma and Biotech. Our customers are looking for unparalleled accuracy in clinical trial results. With the unique combination of AARDEX MEMS® and Haselmeier™ device platforms (for example D-Flex™ and PiccoJect™), we can provide our mutual customers with innovative solutions that help millions of people live healthier and more confident lives."

    Girts Cimermans, CEO of medmix Group, adds: “We are excited about this partnership with AARDEX. Investing and collaborating with an undisputed global leader in patient adherence gives us the distinct advantage of being closer to our customers from an early stage. It also underscores one of our key strategic priorities - to be a technology and innovation leader with strong IP and digital capabilities. We look forward to working closely with the AARDEX team to successfully shape medmix' next phase of growth in the drug delivery segment."

      

     

    About medmix

    medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2’600 employees provide our customers with uncompromising quality, proximity and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss

     

    Inquiries:

    Media Relations: Astrid ZumMallen, Global Corporate Communications Lead

    communications@medmix.com

    Investor Relations: Sheel Gill, Head of Investor Relations
    investorrelations@medmix.com

     

     

    This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.

    CONTACT

    James Amoroso

    Head of Investor Relations

    +41 41 723 73 57

    investorrelations@medmix.com